![](/img/cover-not-exists.png)
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Hillengass, J., Raab, M. S., Schurich, B., Munder, MVolume:
100
Language:
english
Journal:
Haematologica
DOI:
10.3324/haematol.2015.124347
Date:
July, 2015
File:
PDF, 1.65 MB
english, 2015